Pharma stock jumps 17% after UNICEF extends order from company for vaccine supply

Synopsis: The shares surged massively after its supply order extension for its World Health Organisation pre-qualified vaccine, with the order amount increasing to around Rs. 80 crore.

The shares of the company engaged in the business of research, development, manufacture, and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals, and food & nutrition products are in focus after an increase in the value of its supply extension to UNICEF.

With a market capitalization of Rs. 2,487 crore, Panacea Biotec Ltd’s shares on Friday marked a day high of Rs  419.8 per share, up 17 percent from its previous day’s close price of Rs 358.5 per share. The share has given a return of 79 percent over a period of five years.

Significant Order

Panacea Biotec Ltd has received an amended award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of its WHO-prequalified pentavalent vaccine Easyfive-TT. The amendment increases the contract value by a total of US$8.93 million (around Rs 80 crore) for calendar years 2026 and 2027, extending the existing supply arrangement from earlier.

Under the revised terms, the 2026 supply value has been raised by US$2.55 million to US$16.8 million, while the 2027 value has increased by US$2.70 million to US$15.18 million, along with an additional award worth US$3.68 million for 2027. The order involves the international supply of Easyfive-TT to UNICEF to support global immunisation programmes.

The order will further strengthen the company’s segmental revenue base, which stood at Rs 141.13 crore as of September 30, 2025. Of this, vaccine revenues contributed Rs 90.81 crore in Q2, while formulations accounted for Rs 50.32 crore, against a capital employed of Rs 822.86 crore during the same period.

About the company

Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private  Limited, with a commitment to make Innovative Products Affordable and Accessible to the masses. Its goals are supported by their globally accredited USFDA-approved pharmaceutical manufacturing facility at Baddi, WHO pre-qualified facilities for vaccine production at Lalru (Punjab) and Baddi.

Panacea Biotec has a strong and diversified vaccine portfolio, spanning WHO prequalified polio vaccines supplied globally under the UN’s eradication programmes, innovative combination vaccines such as EasyFive and EasySix, and products covering hepatitis B, DTwP-based combinations and IPV. Its pipeline includes next-generation vaccines for dengue, pneumococcal disease and other indications. Making it one of the largest vaccine manufacturers in India.

Financial highlights, revenue declined by 4 percent to Rs 141 crore, corresponding to the same quarter in the last financial year. Accompanied by a huge decline in both EBDIT and Net profit to a negative value of Rs. 17.8 crore and Rs. 14 crore, respectively.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 17% after UNICEF extends order from company for vaccine supply appeared first on Trade Brains.